NextFin News - Nestlé has agreed to sell its mainstream vitamins, minerals and supplements business to Boston-based private equity firm Yellow Wood Partners for $1 billion, stripping out a $1.2 billion-a-year unit as CEO Philipp Navratil narrows the Swiss food giant's focus to the categories where it believes it can win.
The deal, announced September 1, covers seven brands — Nature's Bounty, Osteo Bi-Flex, Ester-C, Gard, Nuun, Puritan's Pride and Sisu — plus Nestlé's U.S. private-label supplements business and the manufacturing, packaging, warehousing and distribution operations behind it. The business generated sales of $1.2 billion in 2025, meaning Nestlé is accepting an implied multiple of roughly 0.8 times annual sales for a unit it has concluded needs "a different approach under dedicated ownership."
The transaction is priced at CHF 0.8 billion and is expected to close in the first half of 2027, subject to regulatory approvals. Nestlé shares ended the day down 0.39%, a muted reaction that underscores how much portfolio surgery investors already expect from Navratil's turnaround. This is not the headline divestment of his tenure; it is one more cut in a program that has already put ice cream, premium water and Blue Bottle Coffee on the selling block.
"This is another important step in the strategic transformation of our portfolio," Navratil said. "We are focusing our resources where we have the strongest competitive advantage. With Nestlé's strong innovation and brand-building capabilities, we are well positioned for growth in the premium, science-led VMS space, where brands such as Solgar and Pure Encapsulations continue to perform strongly. At the same time, the category has evolved, and the mainstream VMS business requires a different approach under dedicated ownership."
What Nestlé Is Selling — and What It Is Keeping
The divestment is not an exit from vitamins. It is a bifurcation. Nestlé is keeping its premium, science-led brands — Solgar and Pure Encapsulations — while handing the value and mainstream tier to a private equity owner built for exactly this kind of asset.
That distinction matters. The retained brands sit in the faster-growing, higher-margin segment of the category, where consumers pay for clinical positioning and where Nestlé's R&D and medical-affairs machinery can compound an advantage. The sold brands — Nature's Bounty, Puritan's Pride and the rest — compete in the mature mainstream tier, where growth is slower, private-label pressure is heavier, and scale in procurement and channel execution matters more than corporate science.
Geographically, the business is predominantly American, with additional presence in Canada and China. That footprint is a good fit for Yellow Wood, a Boston-based middle-market consumer specialist whose entire playbook is built on North American drug, mass and club channels. The private-label supplements operation bundled into the sale is the tell: this is a volume-and-efficiency business, and efficiency is a private equity value-creation lever, not a conglomerate one.
The retained premium brands are not trivial. Nestlé Health Science has spent years building Solgar and Pure Encapsulations into the science-led end of the market, where pricing power is stronger and the customer is less likely to trade down to a supermarket own-label. By splitting the portfolio along that seam, Nestlé is making a judgment about where its corporate capabilities actually earn their keep.
The Buyer: A Corporate Carve-Out Specialist
Yellow Wood Partners is not a generic financial buyer. It is a specialist in exactly the asset Nestlé is selling: a mainstream consumer-health brand portfolio carved out of a multinational conglomerate. The firm's portfolio includes more than 50 consumer brands with roughly $3 billion in retail sales, assembled largely through corporate divestitures — Suave from Unilever in 2023, Elida Beauty (Q-tips, Caress, Ponds, St. Ives) from Unilever in 2024, plus carve-outs from Bayer Pharmaceuticals, Reckitt Benckiser and Haleon.
That track record is the logic of the deal. A mainstream vitamins business inside Nestlé is a rounding error — too small to command corporate attention, too slow-growing to move the group's needle, and starved of the dedicated management focus a private owner can give it. Inside Yellow Wood, the same assets become a core platform. The firm's model is to take undermanaged corporate cast-offs, install focused leadership, and extract growth and margin that the parent never prioritized.
The bet is specific: mainstream supplements are not a dying category, but they are a management-intensive one. They need channel discipline, procurement rigor, and brand reinvestment at a level a CHF 89 billion group is structurally unlikely to give a $1.2 billion unit. Private equity can supply that attention — and can pay for it with leverage and a longer hold period than a public conglomerate's quarterly cycle allows.
Why Navratil Is Selling: The Four-Powerhouse Strategy
The sale is one more cut in a broader restructuring that began when Navratil took the helm. His mandate: rebuild Nestlé around four "powerhouses" — Coffee, PetCare, Nutrition, and Food & Snacks — and remove everything that does not fit. The review has already put the remaining global ice cream business and premium water brands such as San Pellegrino and Perrier into a newly independent company, Peranel, in a transaction valuing the water business at about €4.9 billion ($5.6 billion) with Platinum Equity. Earlier this year the company also sold Blue Bottle Coffee to Centurium Capital. Alongside the portfolio pruning, Navratil has announced 16,000 job cuts — 12,000 white-collar roles and 4,000 in manufacturing and supply chain over two years — as part of a plan to lift annual savings to CHF 1 billion by the end of 2027.
The urgency comes from the numbers. In the first half of 2026, Nestlé posted organic growth of 3.6% and real internal growth of 1.5% — progress, but not enough to satisfy a market that has punished the stock. Net profit fell 31.4% to CHF 3.5 billion, and earnings per share dropped to CHF 1.35 from CHF 1.97 a year earlier. Underlying EPS was nearly flat, down 2.4% to CHF 2.22, and the underlying trading operating margin slipped 10 basis points to 16.4%.
There is, however, cash strength underneath the earnings decline. Free cash flow rose 46.3% to CHF 3.4 billion, and net debt fell to CHF 56.3 billion from CHF 60 billion. Navratil's strategy is to fund the turnaround from within — cutting costs, raising marketing investment to 8.9% of sales, and selling assets that do not earn their place — rather than waiting for top-line acceleration to fix everything.
The vitamins sale fits that template precisely. It converts a low-growth asset into cash for debt reduction and reinvestment in the four core categories, and it removes a unit whose growth trajectory would otherwise dilute the group's aggregate numbers.
The Price: Cheap, or Just Realistic?
At $1 billion for a business doing $1.2 billion in sales, the headline multiple looks low. But it is the right lens for this asset. Mainstream vitamins are a low-growth, working-capital-heavy category; revenue multiples in the 0.5x–1.0x range are not unusual for value-tier supplement brands, while premium, science-led names command materially higher valuations. Nestlé is not fire-selling — it is pricing a business it no longer believes it is the best owner of.
The strategic read is cleaner than the accounting one. Nestlé is swapping a low-multiple, low-growth asset for cash it can redeploy into its four core categories and into debt reduction. For a company trying to re-rate its valuation, that trade makes sense even if the headline price does not dazzle. The $1 billion proceeds equal roughly 0.5% of Nestlé's enterprise value — immaterial as cash, material as a signal that the portfolio review has teeth.
The Mechanism: Why Conglomerates Misallocate Capital
The deeper question this deal answers is why a mainstream vitamins business would ever be worth more outside Nestlé than inside it. The answer is capital allocation, not operations.
Inside a conglomerate, every business competes for the same pool of management attention and investment capital. The allocation process is political as much as financial: the biggest categories, the loudest presidents, the most visible crises win. A $1.2 billion unit in a CHF 89 billion group is structurally invisible. It does not get the pricing reviews, the channel investment, or the brand-building budget it would get as a standalone platform. Over time, that neglect shows up as share loss and margin drift — exactly the pattern that makes the parent conclude the unit "needs a different approach."
This is the classic conglomerate discount in motion. Investors apply a lower multiple to a sprawling group because they cannot underwrite the sum of its parts — they price in the capital they expect to be wasted on businesses the parent should not own. Divestitures attack that discount directly. Each sale removes a piece of the complexity and proves, in the most concrete way available, that management is willing to undo as well as build.
But there is a second-order effect that cuts the other way. When a company sells assets to fund a turnaround, it is also admitting that organic growth in the remaining portfolio is not enough. The market reads these sales two ways: as discipline (management is fixing the portfolio) or as desperation (management cannot grow its way out). The difference between the two readings comes down to one thing — whether real internal growth accelerates after the sales close.
Second-Order Effects: The Conglomerate Discount Unwinds Slowly
The first-order effect of the deal is simple: Nestlé gets $1 billion in cash, sheds a low-growth unit, and sharpens its portfolio narrative. The second-order effect is more important, and more uncertain.
Each divestiture removes a piece of the conglomerate discount. But discounts do not unwind on announcement; they unwind on proof. The market will only re-rate Nestlé when the remaining portfolio grows faster, not when it looks tidier. This sale removes roughly $1.2 billion of annual sales from a group doing about CHF 89 billion — less than 1.5% of revenue. It is a signal, not a transformation by itself. The ice cream exit and the Peranel water deal are larger in dollar terms, but the same logic applies: they clean the portfolio, they do not create growth.
The cross-asset transmission runs the other way too. Private equity is paying $1 billion for a mainstream supplement platform because it believes dedicated ownership can extract margin and growth that a conglomerate cannot. If Yellow Wood succeeds, it validates the carve-out thesis and invites more corporate sellers across consumer health and packaged food. If it struggles, it becomes a cautionary tale about what happens when PE financial engineering meets a category whose consumers are trading down or trading out. The deal is a small bet on a much bigger question: whether the era of the diversified consumer conglomerate is ending, one carve-out at a time.
There is also a peer dimension. Unilever, Haleon, Reckitt and Bayer have all walked the same path — pruning portfolios and handing non-core brands to specialists like Yellow Wood. Nestlé is not a pioneer here; it is a late but large adopter. That matters because late adopters face a harsher test: the market has already seen the playbook, so it demands execution, not announcements.
The Counter-Thesis: This Is Cosmetic Surgery, Not a Cure
The strongest argument against reading too much into this deal is that Nestlé's problem is not its portfolio — it is growth. Selling a 0.8x-sales unit does not make the remaining 98.5% of the company grow faster. The core categories still face private-label competition, emerging-market volatility, and the infant-formula recall that weighed on 2026 results. Navratil's cost cuts and marketing increases can defend margins, but they cannot manufacture the volume growth the stock needs.
There is also execution risk in the strategy itself. A company that sells too much, too fast, can end up smaller without becoming more valuable — a leaner portfolio of slow-growing categories is still a slow-growing portfolio. The four-powerhouse focus is coherent, but coherence is not the same as acceleration. Coffee and pet care are attractive categories, but they are also crowded and, in pet care's case, already re-rated by the market. Paying a premium multiple for a portfolio that grows at the same speed as the old one simply transfers value from Nestlé's shareholders to the sellers of whatever it buys.
Even so, the counter-thesis has a limit. Conglomerates that refuse to prune eventually trade at permanent discounts, because investors price in the complexity they cannot underwrite. Navratil is choosing the opposite risk: cutting first and proving growth later. That is the more defensible sequence, even if the payoff is not guaranteed. Doing nothing was never a viable option for a stock that has underperformed for years.
Cyclical or Structural: What Kind of Turnaround Is This?
This is the judgment that determines whether the deal is a turning point or a line item. The answer is mixed, and the two forces need to be separated.
The near-term headwinds are cyclical. Pricing has done most of the work in Nestlé's recent growth — 2.1% pricing in the first half, against 1.5% real internal growth — and pricing power is mean-reverting. As inflation normalizes, consumers trade down to private label, and the easy price increases run out. That part of the story will revert, and no amount of portfolio surgery changes it.
But the portfolio problem is structural. A CHF 89 billion group with more than 2,000 brands cannot allocate capital efficiently across all of them; that is a feature of the structure, not a cycle. The conglomerate discount does not mean-revert on its own — it only closes when management changes the structure. Navratil's program is a structural fix to a structural problem. Whether it works depends on execution, but the diagnosis is right.
The implication is uncomfortable for investors who want a clean call. The cyclical leg means volume growth will be hard-won even if the portfolio is perfect. The structural leg means the discount will not close until the sales program is complete and the remaining portfolio proves it can grow. Both have to be true for the re-rating to materialize.
What to Watch
- Closing conditions: The deal needs regulatory approval and is not expected to close until the first half of 2027. Any antitrust friction in the U.S. supplement market would be an early warning sign.
- Yellow Wood's playbook: Watch whether the buyer invests in the brands or extracts cost. The private-label supplements operation suggests efficiency is the first lever.
- The pace of divestment: The ice cream exit and the Peranel water transaction set the tempo. The pace of completed sales — not the pace of announcements — is the real metric of Navratil's resolve.
- Volume growth: Real internal growth is the number that separates discipline from desperation. Anything below 2% on a sustained basis undermines the strategy.
- The falsifying signal: If Nestlé's real internal growth does not accelerate above 2% within four quarters of completing this divestiture cycle, the thesis that portfolio focus unlocks growth is wrong — and the market will treat these sales as shrinkage, not strategy.
Outlook: Three Scenarios
Base case: The deal closes in the first half of 2027 as planned. Nestlé uses the proceeds for debt reduction and reinvestment in coffee and pet care. The stock grinds higher on narrative improvement, but the re-rating waits on volume growth.
Upside case: The divestiture program accelerates, the four powerhouses deliver RIG above 3%, and the market begins pricing Nestlé closer to focused peers. The conglomerate discount compresses faster than expected, and the stock re-rates toward the mid-80s Swiss franc range that analysts have targeted.
Downside case: Regulatory delays push the close beyond 2027, or the remaining portfolio's growth stalls despite the pruning. Investors then conclude the surgery was cosmetic and the discount widens, leaving the stock trapped in its low-70s range.
Time horizons matter. In the short term, the deal is neutral-to-positive for sentiment: it confirms Navratil is executing. Over the medium term, the cash helps the balance sheet but does little for growth. Only over the long term — if the focused portfolio genuinely grows faster than the old conglomerate did — does this sale become a turning point rather than a line item.
The takeaway is blunt: Nestlé is not selling vitamins because the category is dying. It is selling the vitamins it cannot win with, so it can fight harder in the vitamins it can. The deal only pays off if the remaining portfolio proves that focus was the constraint all along.
Explore more exclusive insights at nextfin.ai.
